|
|
|
Levi & Korsinsky, LLP Launches an Investigation
Press Release |
2012/01/17 12:10
|
Levi & Korsinsky is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation securities concerning possible violations of federal securities laws.
On January 5, 2012, Integra LifeSciences announced that it received a warning letter from the United States Food and Drug Administration related to quality systems and compliance issues found at its collagen manufacturing facility located in Plainsboro, New Jersey in August 2011. The Company also announced it expects total revenues in the fourth quarter to be approximately 3% below the low end of previously issued guidance. Upon this news, Integra LifeSciences stock fell 20% on January 6, 2012 to close at $24.49 per share; the stock continues to fall, closing on January 10, 2012 at $23.22 per share.
If you own Integra LifeSciences stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/integra-lifesciences-holdings-iart.html .
Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. Attorney advertising. Prior results do not guarantee similar outcomes. |
|
|
|
|
|
|
Ryan & Maniskas, LLP Announces Class Action Lawsuit
Press Release |
2012/01/16 09:29
|
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the Southern District of Ohio on behalf of purchasers of Chemed Corporation common stock during the period between February 15, 2010 and November 16, 2011.
The complaint charges alleges that during the Class Period, defendants issued materially false and misleading statements regarding the Company’s business and prospects. Specifically, defendants failed to disclose the following adverse facts: (1) that the Company engaged in a scheme to fraudulently bill Medicare for hospice services for patients who did not qualify for hospice and fraudulently shifted the costs of those patients from health maintenance organizations that covered those patients prior to enrollment in hospice to the U.S. government; (2) that a significant portion of the Company’s hospice enrollments, revenues and earnings were the direct result of defendants’ scheme to enroll ineligible patients in hospice and fraudulently bill Medicare for hospice services; (3) that, in a complaint filed under seal, a former VITAS manager had accused the Company of engaging in a Company-wide scheme to enroll ineligible patients in hospice and fraudulently bill Medicare; (4) that the Company failed to maintain adequate internal controls and procedures with respect to hospice enrollments and Medicare billings; (5) that the Company’s financial results were materially overstated as a result of defendants’ fraudulent scheme to enroll ineligible patients in hospice; and (6) that, as a result of the foregoing, defendants lacked a reasonable basis for their positive statements about the Company and its prospects.
For more information regarding this class action suit, please contact Ryan & Maniskas, LLP toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/che. |
|
|
|
|
|
|
Michigan Law Firm Adds Top Rated Malpractice Attorney
Press Release |
2012/01/16 09:28
|
The Michigan personal injury law firm of Buckfire & Buckfire, P.C. is proud to announce the addition of medical malpractice attorney Randall M. Blau to our team of already award winning, experienced Michigan medical malpractice lawyers!
Partner and attorney, Lawrence J. Buckfire stated, “We could not be more pleased to add such an extraordinary medical malpractice lawyer to our law firm. Randall Blau was a perfect fit for the law firm, meeting the highest standards and quality that not only we, but our clients, require and expect to be a part of our team. Randall is a respected and highly reputable attorney throughout the State of Michigan and we are proud to have Randy join our law firm as our Michigan medical malpractice lawyer.”
Mr. Blau has obtained millions of dollars in verdicts and settlements for his injured clients. He specializes in medical malpractice, birth injuries, nursing home neglect, wrongful death, and automobile negligence cases. He is a member of the Michigan Association for Justice, the Oakland County Bar Association and the State Bar of Michigan. Randy has been an invited speaker at a variety of legal seminars, an invited member of the Million Dollar Advocates Forum and has been consistently listed in Who's Who in Law throughout his career.
Randall M. Blau earned his Bachelor of Arts degree from Kalamazoo College in 1993 and his Juris Doctor degree from the University of Detroit School of Law in 1996. He is admitted to practice law in state and federal courts throughout Michigan and has handled cases in Ohio, Pennsylvania, Illinois, Minnesota and Florida. He has obtained numerous settlements that have been listed in the Top Ten Settlements of the Year for the State of Michigan multiple times during the last decade.
Prior to joining Buckfire & Buckfire, Randall was a partner with Neuman Anderson, P.C. and senior litigation attorney with Southfield-based Maddin, Hauser, Wartell, Roth & Heller, P.C. He is an active member of a number of charitable and nonprofit organizations, and currently resides in West Bloomfield with his wife and two sons. |
|
|
|
|
|
|
Rigrodsky & Long, P.A. Files Securities Fraud Class Action
Press Release |
2011/12/29 09:47
|
Rigrodsky & Long, P.A. announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired the common stock of IntraLinks Holdings, Inc. between February 17, 2011 and November 10, 2011, inclusive, alleging violations of the Securities Exchange Act of 1934. The case is entitled Thaler v. IntraLinks Holdings, Inc., C.A. No. 11-CV-9528 (S.D.N.Y.). The Complaint names IntraLinks and certain of its officers and directors as defendants.
If you wish to view a copy of the Complaint, discuss this action, or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Noah R. Wortman, Case Development Director of Rigrodsky & Long, P.A., 919 North Market Street, Suite 980 Wilmington, Delaware, 19801 at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/news/intralinks-il.
IntraLinks, together with its subsidiaries, provides software-as-a-service (SaaS) solutions for securely managing content, exchanging critical business information, and collaborating within and among organizations worldwide.
The Complaint asserts that during the Class Period, defendants knew, or recklessly disregarded, that the positive statements concerning the Company’s business prospects, as well as the full year guidance provided by Defendants on February 17, 2011, were materially false and misleading because by end of the first quarter of 2011 a large Enterprise customer informed the Company that it was dramatically reducing its use of IntraLinks’ products going forward and that the Company would have to reducing its earnings expectations as a result. Despite their knowledge of the foregoing, however, defendants failed to disclose that their positive statements about the Company’s business prospects, or the financial guidance issued in February 2011, were no longer accurate in light of the reduced use of the Company’s products by the large Enterprise customer.
If you wish to serve as lead plaintiff, you must move the Court no later than February 4, 2012. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.
http://www.rigrodskylong.com |
|
|
|
|
|
|
Pomerantz Law Firm Has Filed a Class Action
Press Release |
2011/12/25 16:11
|
Shareholders of Pain Therapeutics, Inc. are reminded of the securities class action lawsuit filed against PTIE and certain of its officers. The class action, filed in the United States District Court, Western District of Texas, is on behalf of a class consisting of all persons or entities who purchased PTIE securities during the period from February 3, 2011 through June 23, 2011.
If you are a shareholder who purchased PTIE securities during the Class Period, you have until January 31, 2012 to ask the Court to appoint you as lead plaintiff for the class. A copy of the complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Rachelle R. Boyle at rrboyle@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x350. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
The Complaint alleges that, during the Class Period, PTIE made false and/or misleading statements and/or failed to disclose material facts about a new drug, REMOXY. Specifically, PTIE failed to disclose that REMOXY was not approvable by the U.S. Food and Drug Administration due to chemistry, manufacturing, and control deficiencies that caused inconsistent results during laboratory tests.
www.pomerantzlaw.com. |
|
|
|
|
|
| Law Firm Web Design Information |
| Law Promo has worked with attorneys, lawyers and law firms all over the world in designing beautiful law firm websites that look great on all devices, from desktop computers to mobile phones. Law Promo can construct your law firm a brand new responsive law firm website, or help you redesign your existing site to secure your place in the mobile world. Solo Practice Law Firm Website Design |
|
|
Legal News RSS Feed
